RecruitingEarly Phase 1NCT06552260

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

Studying Glioblastoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ugonma Chukwueke
Principal Investigator
Ugonma Chukwueke, MD
Dana-Farber Cancer Institute
Intervention
Troriluzole(drug)
Enrollment
27 target
Eligibility
18 years · All sexes
Timeline
2025 – 2027

Study locations (3)

Collaborators

National Institutes of Health (NIH) · Biohaven Pharmaceuticals, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06552260 on ClinicalTrials.gov

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Glioblastoma →

← Back to all trials